Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma
Daphne W. Dumoulin, Luca Cantini, Robin Cornelissen, Madelief Vink, Larissa Klaase, Kick Slooff, Nura Tebayna, Joanne M. Mankor, Sara J. Baart, Rudi W. Hendriks, Anne‐Marie C. Dingemans, Marcella Willemsen, Joachim G.J.V. Aerts
Abstract
Purpose: Lurbinectedin is a promising new drug being investigated in pre-treated patients with small cell lung cancer (SCLC) or malignant pleural mesothelioma (MPM). Its clinical activity in the real-world setting has not been investigated yet. Patients and methods: Clinical data of patients with SCLC and MPM who were treated with lurbinectedin were prospectively collected. Comprehensive immune cell profiling by flow cytometry was performed on screening and treating peripheral blood samples. Results: A total of 95 patients (43 SCLC and 52 MPM) were treated, mostly as !3-line of therapy. In the SCLC cohort, a median progression-free survival (mPFS) was 1.5 months (95% CI: 1.4e3.0), and median overall survival was 7.0 months (95% CI: 4.7enot reached). Objective radiological response and disease control rate after 12 weeks were 16% and 28%, respectively. In the MPM cohort, median progression-free survival was 2.8 months (95% CI: 1.4e4.2), and median overall survival was 7.2 months (95% CI: 5.9enot reached). Disease control rate after 12 weeks was 29%, whereas no partial responses were registered. No new safety signals were